Literature DB >> 31877112

Microphthalmia transcription factor expression contributes to bone marrow failure in Fanconi anemia.

Alessia Oppezzo1,2,3, Julie Bourseguin1,2,3, Emilie Renaud1,2, Patrycja Pawlikowska1,2,3, Filippo Rosselli1,2,3.   

Abstract

Hematopoietic stem cell (HSC) attrition is considered the key event underlying progressive BM failure (BMF) in Fanconi anemia (FA), the most frequent inherited BMF disorder in humans. However, despite major advances, how the cellular, biochemical, and molecular alterations reported in FA lead to HSC exhaustion remains poorly understood. Here, we demonstrated in human and mouse cells that loss-of-function of FANCA or FANCC, products of 2 genes affecting more than 80% of FA patients worldwide, is associated with constitutive expression of the transcription factor microphthalmia (MiTF) through the cooperative, unscheduled activation of several stress-signaling pathways, including the SMAD2/3, p38 MAPK, NF-κB, and AKT cascades. We validated the unrestrained Mitf expression downstream of p38 in Fanca-/- mice, which display hallmarks of hematopoietic stress, including loss of HSC quiescence, DNA damage accumulation in HSCs, and reduced HSC repopulation capacity. Importantly, we demonstrated that shRNA-mediated downregulation of Mitf expression or inhibition of p38 signaling rescued HSC quiescence and prevented DNA damage accumulation. Our data support the hypothesis that HSC attrition in FA is the consequence of defects in the DNA-damage response combined with chronic activation of otherwise transiently activated signaling pathways, which jointly prevent the recovery of HSC quiescence.

Entities:  

Keywords:  Bone marrow; Cell Biology; DNA repair; Genetic diseases; Hematology

Mesh:

Substances:

Year:  2020        PMID: 31877112      PMCID: PMC7269568          DOI: 10.1172/JCI131540

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  71 in total

1.  A novel isoform of microphthalmia-associated transcription factor inhibits IL-8 gene expression in human cervical stromal cells.

Authors:  Xiang-Hong Li; A Hari Kishore; Doan Dao; Weiming Zheng; Christopher A Roman; R Ann Word
Journal:  Mol Endocrinol       Date:  2010-06-23

2.  Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors.

Authors:  Tony A Navas; Mani Mohindru; Myka Estes; Jing Ying Ma; Lubomir Sokol; Perry Pahanish; Simrit Parmar; Edwin Haghnazari; Li Zhou; Robert Collins; Irene Kerr; Aaron N Nguyen; Yin Xu; Leonidas C Platanias; Alan A List; Linda S Higgins; Amit Verma
Journal:  Blood       Date:  2006-08-29       Impact factor: 22.113

3.  Awakening dormant haematopoietic stem cells.

Authors:  Andreas Trumpp; Marieke Essers; Anne Wilson
Journal:  Nat Rev Immunol       Date:  2010-03       Impact factor: 53.106

4.  p38 Mitogen-activated protein kinase inhibition enhances in vitro erythropoiesis of Fanconi anemia, complementation group A-deficient bone marrow cells.

Authors:  Johanna Svahn; Tiziana Lanza; Keaney Rathbun; Grover Bagby; Silvia Ravera; Fabio Corsolini; Angela Pistorio; Daniela Longoni; Piero Farruggia; Carlo Dufour; Enrico Cappelli
Journal:  Exp Hematol       Date:  2014-12-19       Impact factor: 3.084

Review 5.  Fanconi anemia proteins and the s phase checkpoint.

Authors:  Pietro Pichierri; Filippo Rosselli
Journal:  Cell Cycle       Date:  2004-06-08       Impact factor: 4.534

6.  Tumor necrosis factor-alpha overproduction in Fanconi's anemia.

Authors:  J C Schultz; N T Shahidi
Journal:  Am J Hematol       Date:  1993-02       Impact factor: 10.047

7.  Hematopoietic stem cells from fancc(-/-) mice have lower growth and differentiation potential in response to growth factors.

Authors:  Michel Aubé; Matthieu Lafrance; Chantal Charbonneau; Isabelle Goulet; Madeleine Carreau
Journal:  Stem Cells       Date:  2002       Impact factor: 6.277

8.  Replication stress is a potent driver of functional decline in ageing haematopoietic stem cells.

Authors:  Johanna Flach; Sietske T Bakker; Mary Mohrin; Pauline C Conroy; Eric M Pietras; Damien Reynaud; Silvia Alvarez; Morgan E Diolaiti; Fernando Ugarte; E Camilla Forsberg; Michelle M Le Beau; Bradley A Stohr; Juan Méndez; Ciaran G Morrison; Emmanuelle Passegué
Journal:  Nature       Date:  2014-07-30       Impact factor: 49.962

9.  A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer.

Authors:  Amita Patnaik; Paul Haluska; Anthony W Tolcher; Charles Erlichman; Kyriakos P Papadopoulos; Janet L Lensing; Muralidhar Beeram; Julian R Molina; Drew W Rasco; Rebecca R Arcos; Claudia S Kelly; Sameera R Wijayawardana; Xuekui Zhang; Louis F Stancato; Robert Bell; Peipei Shi; Palaniappan Kulanthaivel; Celine Pitou; Lynette B Mulle; Daphne L Farrington; Edward M Chan; Matthew P Goetz
Journal:  Clin Cancer Res       Date:  2015-11-18       Impact factor: 12.531

Review 10.  Activin/Nodal signalling in stem cells.

Authors:  Siim Pauklin; Ludovic Vallier
Journal:  Development       Date:  2015-02-15       Impact factor: 6.868

View more
  3 in total

1.  Global miRNA expression of bone marrow mesenchymal stem/stromal cells derived from Fanconi anemia patients.

Authors:  Ilgin Cagnan; Mustafa Keles; Ayse Gokce Keskus; Melike Tombaz; Ozge Burcu Sahan; Fatima Aerts-Kaya; Duygu Uckan-Cetinkaya; Ozlen Konu; Aysen Gunel-Ozcan
Journal:  Hum Cell       Date:  2021-11-18       Impact factor: 4.174

Review 2.  The underestimated role of the microphthalmia-associated transcription factor (MiTF) in normal and pathological haematopoiesis.

Authors:  Alessia Oppezzo; Filippo Rosselli
Journal:  Cell Biosci       Date:  2021-01-13       Impact factor: 7.133

3.  Fanconi anemia A protein participates in nucleolar homeostasis maintenance and ribosome biogenesis.

Authors:  Anna Gueiderikh; Frédérique Maczkowiak-Chartois; Guillaume Rouvet; Sylvie Souquère-Besse; Sébastien Apcher; Jean-Jacques Diaz; Filippo Rosselli
Journal:  Sci Adv       Date:  2021-01-01       Impact factor: 14.136

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.